Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-03-12
1999-08-10
Moezie, F. T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544318, 544408, 546 77, 546 78, 546 14, A61K 3147, A61K 3158
Patent
active
059359684
ABSTRACT:
The present invention provides for a method of treating polycystic ovary syndrome in a subject in need of such treatment comprising the administration of a therapeutically effective amount of a compound of structural formula I: ##STR1## to the subject. The present invention further provides for a method for improving fertility and the response to in vitro fertilization (I.V.F.), comprising administration of therapeutically effective amount of compound of structural formula I to the subject. Further, the present invention provides for compositions useful in the methods of the present invention, as well as a method of manufacture of a medicament useful for treating polycystic ovary syndrome or for improving fertility or the response to in vitro fertilization (I.V.F.).
REFERENCES:
patent: 4760071 (1988-07-01), Rasmusson et al.
patent: 5264427 (1993-11-01), Brodie et al.
patent: 5302589 (1994-04-01), Fry et al.
patent: 5359071 (1994-10-01), Durette et al.
patent: 5512555 (1996-04-01), Waldstreicher
patent: 5525608 (1996-06-01), Adams et al.
patent: 5543406 (1996-08-01), Andrews et al.
patent: 5543417 (1996-08-01), Waldstreicher
patent: 5547957 (1996-08-01), Gormley et al.
patent: 5565467 (1996-10-01), Batchelor et al.
patent: 5693809 (1997-12-01), Durette et al.
patent: 5696266 (1997-12-01), Humphrey
patent: 5719158 (1998-02-01), Durette et al.
patent: 5739137 (1998-04-01), Durette et al.
patent: 5760046 (1998-06-01), Gormley et al.
Ciotta et al., Fertility & Sterility, vol. 64, No. 2, (1995), pp. 299-306, "Clinical and endocrine effects of finasteride, a 5-alpha-reductase inhibitor, in women with idiopathic hirsutism".
Stewart et al., The Lancet, vol. 335, (1990), pp. 431-433, "5alpha-reductase activity in polycystic ovary syndrome".
Agarwal et al., J. Clinc. Endoc. Metab., vol. 81 (1996), pp. 3686-3691, "A mechanism for the suppression of estrogen production in polycycstic ovary syndrome".
Fruzzetti et al., J. Clin. Endoc. Metab., vol. 79 (1994), pp. 831-835, "Effects of finasteride, a 5-alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women".
Haning Jr., et al., J. Steriod Biochem. Molec. Biol., vol. 59, (1996), pp. 199-204, 5alpha-reductase 1 and 2 expression and activity in human ovarian follicles, stroma and . . .
Rodin et al., N. Engl. J. of Med., (1994), vol. 330, pp. 460-465, "Hyperandrogenism in polycystic ovary syndrome".
Tolino et al., Fertility and Sterility, vol. 66, No. 1, (1996), p. 61-65, "Finasteride in the treatment of hirsutism: New therapeutic perspectives".
Ehrmann et al., Endocrine Reviews, vol. 16 (1995), pp. 322-352, "Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion".
Erickson et al., The Ovary, (1993), Chapter 28, pp. 561-579.
Wong et al., J. Clin. Endoc. Metab., vol. 80 (1995), pp. 233-238, "A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women".
Moghetti et al., J. Clin. Endoc. Metab., vol. 79 (1994), pp. 1115-1121, "Clinical and hormonal effects of the 5alpha-reductase inhibitor finasteride in idiopathic hirsutism".
Rittmaster, Lancet, vol. 349 (1997), pp. 191-195, "Hirsutism".
Castello et al., Fertility and Sterility, vol. 66 (1996), pp. 734-740, "Outcome of long-term treatmentwith the 5alpha-reductase inhibitor finasteride in idiopathic hirsutism . . . "
Harris Georgianna S.
Waldstreicher Joanne
Fitch Catherine D.
Merck & Co. , Inc.
Moezie F. T.
Winokur Melvin
LandOfFree
Methods for treating polycystic ovary syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating polycystic ovary syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating polycystic ovary syndrome will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1120467